The Economic Times
English EditionEnglish Editionहिन्दीગુજરાતી
| 26 September, 2020, 01:34 AM IST | E-Paper
Search
+

    Kiran Kabtta Somvanshi

    Editor, ET

    Articles by the author

    Soon, get deeper insights into what a company is all about, and its social compassETIG Analysis: Pharma companies involved in rolling out Covid-19 treatments face ESG implications$2 billion war chest to help Piramal tide over Covid crisisWill the launch of Favipiravir mark the turnaround for Glenmark Pharma?
    Indian pharma back in favour on improving fundamentalsFive trends that are likely to play out for the FMCG sector due to CovidLike DRL, will Wipro too see a turnaround under expat CEO?Global engines fire up again, Europe makes steady start
    Cipla's Q4 results could set the tone for what to expect from its peers for the quarterArt of Clean Living: Covid delivers what Swachh Bharat aimed forCovid-19 is proving to be the litmus test for ESG investingGoldman picks GRANOLAS in Europe. Does India have any for investors?
    India Inc’s traditional CSR may end up in containmentIs ITC stock a dividend buy? Wait for lockdown updateAurobindo’s regulatory woes cast a shadow on strong fundamentalsBeaten-down pharma stocks turn healthy bets for investors
    It might be a little too early to invest in Fortis HealthcareHUL stock may be peaking out after a gulp of HorlicksStrong HUL can make Horlicks buy workAn old hand’s back, but can Lupin and he make it count?
    Sun buyback could be a good opportunity to book profitsWhat does a change of management mean for Jyothy Labs and its investors?One in every three CEO changes in the past three years has led to positive returns on the boursesAlmost 90% of men & women globally are biased against women: UNDP report
    Five factors to consider before you invest in ITCAnalysis: With CSR kitty bulging this year, increasing number and variety of donees are appealing companies for fundsWhen compelled to do good, how has India Inc fared?Is specialty business ‘a go or a no-go’ segment for pharma companies?
    Buffett's Big Idea: Women and non-wealthy directors on boardsWhy a new expat CEO may be good news for Dr Reddy’sAs FIIs turn ESG-conscious, Indian markets to have an implicationInventory buffer to keep pharma healthy for now
    Investors can wait for Sun to come upTaxation not the only concern for ITC stockHUL can go for strategic price hikes, cigarettes a drag on ITCBudget to have a bigger impact on HUL & ITC stocks than Q3 numbers
    Sebi investigated an unprecedented number of alleged insider trading violations in FY19India commands the top score on the Women, Business and Law Index 2020 in South Asia4045 times is the highest CEO pay ratio in India Inc for FY19Will new CEOs at Tata Global, Bajaj Consumer improve performance?
    Investing in indices and funds with ESG focus can pay offInvesting in indices and funds with ESG focus can pay offProbes by Sebi treble in four years, but closure rate faltersFive trends that defined India Inc's corporate governance standards in 2019
    Vision 2020: Miles to go before goals are reachedFMCG companies’ bet on consumer services business not paying offWomen on boards double in five years, but representation still lowLessons from Zee: What to read when investing in a cash-cow firm
    India Inc boards bigger, more independent than 5 years agoIndian boards are meeting a tad more oftenRegulations may prove to be another Patanjali for FMCG firmsInvestors can wait for Sun to shine in Japan and China
    Governance issues most important for investors in IndiaLupin looks to sell Japanese arm Kyowa for $600 millionBiocon’s $1-billion biologics sales target ‘looks lofty’Cipla may raise bar with digital therapeutics push
    ITC still mainly a cigarette company, and still a dividend stockHUL’s resilience amid slump just one of the reasons to be investedHUL Q2 results: Focus on demand outlook, GSK dealChinese growth shot’s some years away for pharma companies
    Pharma cos need to quickly learn how to balance interests of investors and patientsITC on a good wicket, can it score big?Will companies turn CSR into CIR?
    Will companies turn CSR into CIR?
    23 Sep 2019 11:49 AM IST
    In beaten down Pharma Inc, Aurobindo still offers hope
    India Inc gradually finds a purpose beyond profitIndia Inc gradually finds a purpose beyond profitSebi clean chit is one issue less for Sun Pharma to worry aboutWill Nestle too disappoint Street after likely entry into Nifty?
    Why Indian pharma needs more expats on boardsFMCG cos’ CEOs join boards of peers for exchange of ideasIs Sun Pharma on the road to recovery?Sexual harassment plaints at Nifty companies hit a record
    Corporate governance gets its due
    Corporate governance gets its due
    31 Jul 2019 10:10 AM IST
    Strong operating growth, cost control lift HUL’s show in April-June qtrHUL may not buck slowdown, but stock’s still top FMCG playPharma doing a clinical trial of own model; no quick fix though
    Higher I-T cess leaves India Inc a worried lotWhy a CFO’s exit should make investors take noteIs Piramal Enterprises a misfit in healthcare indices?How Budget failed to boost the FMCG sector
    HUL is the most valuable FMCG co. Here are five reasons whyFMCG copmanies happy to serve a billion at home, limit their global spreadTata Global seeks new captain to power its FMCG ambitionsInvestors with a risk appetite may opt for Fortis over Apollo
    Four Cs to determine the course for Indian pharma‘Frequent CEO changes hurt shareholder returns’Five ways pharmaceutical and healthcare sectors can be ‘Modified’Sun in transition, stock to stay in range
    March quarter results announced today are likely to go unnoticedElections results don’t matter much for pharma stocksIndian Pharma’s incentives to do business in US on steady declineIncense winning mosquito war, repellent makers feel the bite
    HUL investors could expect some time & price correctionHUL’s March quarter show may be tepid on muted spendingSubstandard drugs are a bigger problem for India than fakesSubstandard drugs are a bigger problem for India than fakes
    The Economic Times